Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
about
Point-of-prescription interventions to improve antimicrobial stewardshipAntibiotics for ventilator-associated pneumonia.Using Procalcitonin to Guide Antibiotic Therapy.Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community StudyBurden of Hospital Acquired Infections and Antimicrobial Use in Vietnamese Adult Intensive Care Units.Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United StatesEvaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Incidence Rate of Healthcare-Associated Clostridium difficile Infection: A Non-Randomized, Stepped Wedge, Single-Site, Observational Study.Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infectionsPiperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.Long-term outcomes of an antimicrobial stewardship program implemented in a hospital with low baseline antibiotic use.Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012.Effects of a Syndrome-Specific Antibiotic Stewardship Intervention for Inpatient Community-Acquired Pneumonia.Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat.Risk Factors for Bacteremia in Patients With Urinary Catheter-Associated Bacteriuria.Retrospective observation of drug susceptibility of Candida strains in the years 1999, 2004, and 2015.Antibiotic use in US hospitals: quantification, quality measures and stewardship.Building an Antimicrobial Stewardship Program: Cooperative Roles for Pharmacists, Infectious Diseases Specialists, and Clinical Microbiologists.Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.Clinical condition and comorbidity as determinants for blood culture positivity in patients with skin and soft-tissue infectionsThe Italian Society of Internal Medicine choosing wisely campaign.What are the similarities and differences in antimicrobial prescribing between Australian public and private hospitals?Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box.Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.Computerized pharmacy surveillance and alert system for drug-related problems.Sustained impact of a computer-assisted antimicrobial stewardship intervention on antimicrobial use and length of stay.Patients as Patches: Ecology and Epidemiology in Healthcare Environments.Antibiotic Use in Small Community Hospitals.Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection.Failure of outpatient antibiotics among patients hospitalized for acute bacterial skin infections: What is the clinical relevance?Antibiotic Stewardship in Small Hospitals: Barriers and Potential Solutions.Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing.Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.Vaccines for Healthcare-associated Infections: Promise and Challenge.When it comes to stewardship, it's time to get with the programmers.Identifying Antimicrobial Stewardship Targets for Pediatric Surgical Patients.Increasing evidence of the nephrotoxicity of piperacillin/tazobactam and vancomycin combination therapy - what is the clinician to do?
P2860
Q26823984-31577738-1994-4F20-BA17-7DEAE1C0A310Q30243877-8CC35C63-9A8E-41C8-8A84-4F2665AB056AQ33629591-95BFDECF-3EDC-4FE8-AF09-50773B412FD8Q33904263-840B78CC-1CC1-496E-BAE0-055AE97E483FQ35908137-06424239-3B22-4295-B45D-4CB3D14F62DEQ35997443-ED912080-E41E-485D-81DC-6F6648A0246CQ36053985-99BF6215-9E9C-4E1E-A66C-4FBDCAF58396Q36292068-720A4D5A-6977-4380-9E28-0C401B34A0FEQ36760879-B9C6E122-2E7E-42A3-A76C-D07BD1FF0214Q36813038-76313A4B-3C7E-46FB-867A-EB9540E97DC9Q36933333-41E60475-F822-40C5-A86A-378832F64655Q36973200-B67E1705-5788-4B30-A1E4-C126D2FD0CCDQ37338130-B4C17849-229A-47C4-8E23-CE9C32C38262Q37416986-43568034-3423-44B7-BC26-0BE3CEC07870Q37509403-F419415A-767B-4319-90EE-A3EE5D318427Q37666788-0A412DEF-A9EA-48C4-AD1E-90491281CEA3Q38449948-E3E139BE-3520-4DB0-9AE6-C73165AD8A8DQ38568768-131D1E69-C501-4243-93A9-3B430F59543DQ38691351-81C2FE2E-EC1C-4443-9BCA-3F91CF954414Q38739168-D351651A-F03B-465E-8949-13E56154FBC0Q38800531-5C82FCDF-14AF-46AF-B319-E14E3CE616D7Q38832142-2112D9D6-E58F-4A06-8002-7F25D173C6EDQ38967152-56166D8F-345F-4F25-AC56-952D2D09DA63Q39025281-6DB53349-C837-4519-8E8D-EAEC99FB8327Q39025617-18404D11-6C5F-4EF3-8D2C-6503FC2544D3Q39080561-7BF4600A-512D-4B29-B959-51668FBB151DQ39270112-22FADE29-5131-4922-9853-98AE9A9E44A8Q39330731-5FEA442B-735B-45B7-89CC-A508CA91848CQ40066416-523F583E-7502-4669-9E53-53F9AD7516EDQ40115127-7CE861E3-00B5-4CE7-8751-E02277ED4FE7Q40215156-66216BC9-DC63-46BC-BFC3-3B02477BE400Q40273393-0F5E470B-A3AC-4BE8-A974-5DD437B314CAQ40342746-9DAF71F1-669D-4CB6-92A7-4A83D78D2B41Q40343676-649AF8C5-1934-4963-90A8-676FD003ACF1Q40363114-45380D59-0579-448B-A0F5-897B6CABD13AQ40420577-718C1C84-73F0-4E84-BB36-6824F5D0FC10Q40665389-56CF9BE9-6DBE-4EED-988E-89089856ACD1Q40897687-6B6E1868-888A-4F68-96B0-C783643B7AE6Q40981759-831D41DA-93E9-425F-8EF3-16417607F699Q41987133-E6222B56-CA0B-46E6-A709-11CF8FBACC4F
P2860
Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
@en
type
label
Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
@en
prefLabel
Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
@en
P2093
P356
P1476
Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.
@en
P2093
Deborah L Thompson
Emerging Infections Program He ...... ial Use Prevalence Survey Team
Joelle Nadle
Jonathan R Edwards
Katherine Richards
Marion A Kainer
Melinda M Neuhauser
Richard Rodriguez
Sarah J Janelle
Scott K Fridkin
P304
P356
10.1001/JAMA.2014.12923
P407
P577
2014-10-01T00:00:00Z